Evidence map›Paper›PMID 37490235›Full record

ReviewInternational journal of hematology2023

Successful allogeneic hematopoietic stem cell transplantation in a patient with type I CD36 deficiency: a case study and literature review.

Shuhei Okuyama, Masahiko Sumi, Ryuto Ishikawa, Tsutomu Shishido, Daisuke Koyama, Toshimitsu Ueki, Daisuke Takahashi, Hironori Kobayashi, Hikaru Kobayashi, Nelson Hirokazu Tsuno

Abstract readReviewCase Reports
PubMed Publisher
In one paragraph

Review in International journal of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Shuhei OkuyamaDepartment of Hematology, Nagano Red Cross Hospital, Nagano, Japan. okuyama442@gmail.com.ORCID http://orcid.org/0000-0001-6948-2341
Masahiko SumiDepartment of Hematology, Nagano Red Cross Hospital, Nagano, Japan.
Ryuto IshikawaDepartment of Hematology, Nagano Red Cross Hospital, Nagano, Japan.
Tsutomu ShishidoDepartment of Hematology, Nagano Red Cross Hospital, Nagano, Japan.
Daisuke KoyamaDepartment of Hematology, Nagano Red Cross Hospital, Nagano, Japan.
Toshimitsu UekiDepartment of Hematology, Nagano Red Cross Hospital, Nagano, Japan.
Daisuke TakahashiCentral Blood Institute, Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan.
Hironori KobayashiLaboratory Department, Japanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan.
Hikaru KobayashiDepartment of Hematology, Nagano Red Cross Hospital, Nagano, Japan.
Nelson Hirokazu TsunoLaboratory Department, Japanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan.
Nagano Red Cross Hospital · JPJapanese Red Cross Society, Japan · JPYamagata Prefectural Central Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCD36-deficient individuals may produce anti-CD36 antibodies through antigenic exposure to CD36, in situations including blood transfusions. Therefore, allogeneic hematopoietic stem cell transplantation (HSCT) from CD36-positive donors to CD36-negative patients remains a challenge. CASE REPORT: A 64-year-old man with acute myeloid leukemia became refractory to platelet transfusions during chemotherapy. Anti-CD36 antibodies without anti-HLA antibodies were detected in serum, and the absence of CD36 expression on platelets and monocytes confirmed type I CD36 deficiency. The patient achieved complete remission, and received maintenance therapy with CD36-negative platelet transfusions. However, he relapsed soon afterward, and thus underwent peripheral blood stem cell transplantation (PBSCT) from a CD36-positive unrelated donor. The anti-CD36 antibody titer had decreased before the transplant, and the PBSCT-course was uneventful. The patient has been well without any complications associated with CD36 status mismatch. DISCUSSION: The few reports of allogeneic HSCT in patients with CD36 deficiency have suggested that anti-CD36 antibodies could be involved in several post-transplant complications, such as delayed platelet recovery, transfusion refractoriness, and transfusion-related acute lung injury. Our present case confirmed that stem cell transplantation from CD36-positive donors to negative patients is feasible, when it includes careful prior assessment of anti-CD36 antibody titers and interventions to attenuate them.

Indexed as

Blood Platelet DisordersHematopoietic Stem Cell TransplantationBlood PlateletsGenetic Diseases, InbornHumansMaleMiddle AgedUnrelated DonorsAnti-CD36CD36 deficiencyHematopoietic stem cellPatient blood managementPlatelet transfusion refractoriness

Identifiers

PMID37490235
OpenAlexW4385230237

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.